lapatinib has been researched along with phenytoin in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (phenytoin) | Trials (phenytoin) | Recent Studies (post-2010) (phenytoin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 14,105 | 758 | 1,497 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdel Latif, NS; El-Kalaawy, AM; Lamie, PF; Philoppes, JN; Rashed, LA | 1 |
1 review(s) available for lapatinib and phenytoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and phenytoin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lithium Carbonate; Male; Mice; Molecular Structure; Pilocarpine; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Status Epilepticus; Structure-Activity Relationship | 2021 |